{"entity":{"id":"paper-portec-3-lancet-oncol-2018","kind":"paper","name":"PORTEC-3: adjuvant chemoradiotherapy versus radiotherapy alone for high-risk endometrial cancer","aka":[],"tldr":"Adding cisplatin during pelvic radiotherapy and four cycles of carboplatin-paclitaxel afterwards improved failure-free survival in high-risk endometrial cancer, most clearly in stage III and serous cancers, at the cost of more toxicity.","summary":"Phase 3 trial of 686 women with high-risk endometrial cancer (stage I grade 3 with deep invasion or lymphovascular invasion, stage II to III, or serous or clear cell histology) randomised to pelvic radiotherapy alone or radiotherapy with concurrent cisplatin followed by four cycles of carboplatin-paclitaxel.\n\nFive-year failure-free survival was 75.5 versus 68.6 percent (hazard ratio 0.71); overall survival was 81.4 versus 76.1 percent, significant only on longer follow-up, with the largest benefit in stage III and serous disease.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2018","url":"https://doi.org/10.1016/S1470-2045(18)30079-2"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29449189/"}],"tags":[],"related":[],"cancers":["endometrial-p53-abnormal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["portec-3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30079-2","pmid":"29449189","authors":"de Boer SM, Powell ME, Mileshkin L, et al.","paperType":"rct","findings":["Five-year failure-free survival 75.5 percent vs 68.6 percent; hazard ratio 0.71.","Updated five-year overall survival 81.4 percent vs 76.1 percent."],"whatItMeans":"Chemoradiotherapy is the standard for stage III and for p53-abnormal or serous endometrial cancer; for other stage I to II tumours radiotherapy alone or brachytherapy suffices.","caveats":["Grade 3 or worse adverse events 60 percent vs 12 percent during treatment; persistent neuropathy.","The molecular sub-analysis shows benefit is concentrated in p53-abnormal tumours."],"changedPractice":true,"participants":686},"route":"/key-papers/paper-portec-3-lancet-oncol-2018/","neighbours":{"cancer":[{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/"}],"trial":[{"id":"portec-3","kind":"trial","name":"PORTEC-3","route":"/trials/portec-3/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}